Responses
Regular and young investigator award abstracts
Immuno-conjugates and chimeric molecules
627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
